An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -51,321 | -43,799 | -31,052 | -16,617 | -64,732 |
| Depreciation Amortization | -3,279 | -2,712 | -1,981 | -1,091 | -2,855 |
| Accounts payable and accrued liabilities | 641 | -965 | -791 | -243 | 553 |
| Other Working Capital | -3,121 | -4,641 | -3,493 | -1,924 | 5,168 |
| Other Operating Activity | 7,823 | 8,133 | 5,340 | 2,282 | 8,578 |
| Operating Cash Flow | $-49,257 | $-43,984 | $-31,977 | $-17,593 | $-53,288 |
| Cash Flows From Investing Activities | |||||
| Purchase Of Investment | -46,751 | -22,371 | -12,590 | N/A | -132,178 |
| Sale Of Investment | 101,340 | 83,840 | 55,340 | 26,290 | 88,900 |
| Investing Cash Flow | $54,589 | $61,469 | $42,750 | $26,290 | $-43,278 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 372 | 372 | 124 | 349 | 84,994 |
| Common Stock Repurchased | N/A | N/A | 225 | N/A | N/A |
| Financing Cash Flow | $372 | $372 | $349 | $349 | $84,994 |
| Beginning Cash Position | 15,647 | 15,647 | 15,647 | 15,647 | 27,219 |
| End Cash Position | 21,351 | 33,504 | 26,769 | 24,693 | 15,647 |
| Net Cash Flow | $5,704 | $17,857 | $11,122 | $9,046 | $-11,572 |
| Free Cash Flow | |||||
| Operating Cash Flow | -49,257 | -43,984 | -31,977 | -17,593 | -53,288 |
| Free Cash Flow | -49,257 | -43,984 | -31,977 | -17,593 | -53,288 |